Key Statistics for 2191
|Current P/E Ratio (ttm)
Relative P/E vs.
|Earnings Per Share (JPY) (ttm)
|Est. EPS (JPY) (12/2013)
|Est. PEG Ratio
|Market Cap (M JPY)
|Shares Outstanding (M)
|30 Day Average Volume
|Dividend Indicated Gross Yield
|Cash Dividend (JPY)
|5 Year Dividend Growth
|Next Earnings Announcement
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for 2191
- Net Income (M/JPY)
tella, Inc. provides cancer treatment and know-hows to contracted medical institutions. The company supports these medical institutions by offering dendritic cell vaccine treatment and other technology that chemical therapy and actinotherapy combined.
More Company Profile & Key Executives for 2191
|Yuichiro YazakiPresident/Founder||Naoko IinoDirector|
|Ryohei YamamotoDirector||Hideki MatsubaraDirector|
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.